We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phosphodiesterase type 5 inhibitor tadalafil reduces prostatic fibrosis via MiR-3126-3p/FGF9 axis in benign prostatic hyperplasia.
- Authors
Li, Tiewen; Zhang, Yu; Zhou, Zeng; Guan, Lvxin; Zhang, Yichen; Zhou, Zhiyuan; Wang, Wenhao; Zhou, Xuehao; Cui, Di; Jiang, Chenyi; Ruan, Yuan
- Abstract
Myofibroblast buildup and prostatic fibrosis play a crucial role in the development of benign prostatic hyperplasia (BPH). Treatments specifically targeting myofibroblasts could be a promising approach for treating BPH. Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, holds the potential to intervene in this biological process. This study employs prostatic stromal fibroblasts to induce myofibroblast differentiation through TGFβ1 stimulation. As a result, tadalafil significantly inhibited prostatic stromal fibroblast proliferation and fibrosis process, compared to the control group. Furthermore, our transcriptome sequencing results revealed that tadalafil inhibited FGF9 secretion and simultaneously improved miR-3126-3p expression via TGFβ1 suppression. Overall, TGFβ1 can trigger pro-fibrotic signaling through miR-3126-3p in the prostatic stroma, and the use of tadalafil can inhibit this process.
- Publication
Biology Direct, 2024, Vol 19, Issue 1, p1
- ISSN
1745-6150
- Publication type
Article
- DOI
10.1186/s13062-024-00504-y